Category: Oncology

oncology

Functional status and co-morbidities trump chronological age for choosing treatment for elderly patients with AML

April 4, 2011
norbert vey Functional status and co morbidities trump chronological age for choosing treatment for elderly patients with AML

Norbert Vey

ROME—It is not acceptable to deny patients with acute myeloid leukaemia the most effective treatments on grounds of age alone, according to Norbert Vey, Professor of Haematology at the Universitée de la Méditerrannée, in Marseille and Head of the Leukaemia/MDS Programme at the Institut Paoli Calmettes. He talks with ecancer radio about the scope for improving treatment for elderly patients who have AML.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Big outcome gains from individualised treatment for elderly patients with blood cancers

April 4, 2011
reinhard stauder Big outcome gains from individualised treatment for elderly patients with blood cancers

Reinhard Stauder

ROME—Clinicians will need increasingly to specialise in geriatric oncology to tackle the growing un-met need for appropriate treatment in elderly patients with blood cancers, according to a leading European expert talking at the Rome conference on Blood Cancer in the Elderly. Professor Reinhard Stauder of Innsbruck University tells ecancer radio about the steps he and his colleagues are taking to ensure appropriate therapy for older cancer patients.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Co-operation: the key to managing elderly patients with cancer

April 4, 2011
antonio cherubini Co operation: the key to managing elderly patients with cancer

Antonio Cherubini

ROME—Co-operation between geriatricians and cancer doctors was being urged at the Rome conference on Blood Cancer In The Elderly by Antonio Cherubini, Associate Professor of Geriatrics at the University of Perugia in Italy. He discusses with ecancer radio his reasons for favouring multi-disciplinary care to achieve individualised effective management.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Geriatric oncology: facing up to the population time bomb

April 2, 2011
richard sullivan Geriatric oncology: facing up to the population time bomb

Richard Sullivan

ROME—Cancer doctors need to face up to the challenge of the global population time bomb of elderly patients with cancer, according to Richard Sullivan, Director of International Affairs at Kings Health Partners Integrated Cancer Centre, based in Guys Hospital, London. He told the Rome conference on Blood Cancer in the Elderly that many older patients with cancer are fit enough to receive the most effective treatments, so better therapy outcomes can be achieved than is often expected. He explains to ecancer radio what needs to be done to face up to this challenge.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Why elderly patients with multiple myeloma should get novel agents and how to minimise yoxicities

April 2, 2011
michele cavo Why elderly patients with multiple myeloma should get novel agents and how to minimise yoxicities

Michele Cavo

ROME—Age should be no barrier to the use of novel agents for treating elderly patients with multiple myeloma, according to Michele Cavo, Associate Professor of Haematology at the University School of Medicine, Bologna, Italy, who addressed the European Expert Forum on Blood Cancer In The Elderly in Rome (19-20 March 2011). He tells eancer radio about the clinical decision-making processes needed to achieve better treatment and longer remissions among elderly patients, and explains why each patient should have therapy planned on an individual basis rather than according to chronological age.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Rome Conference To Show Age Is No Barrier To Effective Cancer Treatment

March 14, 2011
matti aapro Rome Conference To Show Age Is No Barrier To Effective Cancer Treatment

Matti Aapro

GENEVA—In advance of the European Expert Forum on Blood Cancer in the Elderly — being held in Rome — there has been a call for action that doctors should avoid denying older patients cancer therapies on the basis of age alone. Dr Matti Aapro — Executive Director of the International Society for Geriatric Oncology and Dean of the Multidisciplinary Oncology Institute in Genolier, Switzerland — talks with eCancer Radio about the difference between chronological and biological age, and highlights some of the practical messages for cancer doctors attending the Rome conference.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Immunotoxin Brentuximab Vedotin (SGN 35) — Active In Refractory/Relapsed Hodgkin’s Disease And Anaplastic Large T Cell Lymphoma

January 6, 2011
george canellos 3 Immunotoxin Brentuximab Vedotin (SGN 35) — Active In Refractory/Relapsed Hodgkin’s Disease And Anaplastic Large T Cell Lymphoma

George Canellos

ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology annual meeting in Orlando. The same agent has also been found to be active against anaplastic large T-cell lymphoma in a study presented at the ASH conference by a group from Seattle. eCancer Radio’s Haematology Editor George Canellos from the Dana-Farber Cancer Institue and Harvard University discusses the clinical promise of these findings for advancing further response rates and “permanent remissions” in Hodgkin’s Disease.

ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

“Obligate Radiotherapy” Makes Stanford V Less Favourable Than ABVD Chemotherapy For Hodgkin’s Disease

December 11, 2010
george canellos 3 “Obligate Radiotherapy” Makes Stanford V Less Favourable Than ABVD Chemotherapy For Hodgkin’s Disease

George Canellos

ORLANDO—In new research the Stanford V chemotherapy regimen for Hodgkin’s Disease was inferior to ABVD because it required “obligate radiotherapy” — according to George Canellos of the Dana-Farber Cancer Institute in Boston — who gives eCancerRadio his opinion of two papers presented at the American Society of Hematology annual meeting (December 3-7, 2010) held in Orlando: one from California comparing the two regimens in patients with stage I/II bulky mediastinal Hodgkin Lymphoma; the second from Illinois in which the same comparison was made in patients who had locally extensive and advanced stage disease.

ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Immunotoxin Brentuximab Vedotin (SGN 35) — Active In Refractory/Relapsed Hodgkin’s Disease And Anaplastic Large T Cell Lymphoma

December 11, 2010
george canellos 2 Immunotoxin Brentuximab Vedotin (SGN 35) — Active In Refractory/Relapsed Hodgkin’s Disease And Anaplastic Large T Cell Lymphoma

George Canellos

ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology annual meeting in Orlando. The same agent has also been found to be active against anaplastic large T-cell lymphoma in a study presented at the ASH conference by a group from Seattle. eCancer Radio’s Haematology Editor George Canellos from the Dana-Farber Cancer Institue and Harvard University discusses the clinical promise of these findings for advancing further response rates and “permanent remissions” in Hodgkin’s Disease.

ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Lenalidomide After Autologous Transplantation Delays Myeloma Progression

December 11, 2010
phillip mccarthy Lenalidomide After Autologous Transplantation Delays Myeloma Progression

Philip McCarthy

ORLANDO—Lenalidomide maintenance therapy extended times to disease progression among patients whose multiple myeloma had been treated with autologous stem cell transplantation in a phase III study reported at the American Society of Hematology annual meeting (December 3-7, 2010) in Orlando. Philip McCarthy, Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York, discusses the clinical implications of his group’s findings with eCancer Radio.

ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Large Cell Lymphoma: Immuno-Chemotherapy Without Radiotherapy Cures Patients With Large B Cell Lymphoma

December 11, 2010
george canellos Large Cell Lymphoma: Immuno Chemotherapy Without Radiotherapy Cures Patients With Large B Cell Lymphoma

George Canellos

ORLANDO—Primary mediastinal large B cell lymphoma responded excellently to a dose-dense schedule of R-CHOP immuno-chemotherapy followed by ICE chemotherapy — without the need for radiotherapy — in a study from New York reported at the American Society of Hematology annual meeting in Orlando. eCancer Radio’s Hematology Editor, George Canellos, of the Dana-Farber Cancer Institute in Boston discusses the importance of these findings.

ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Also posted in eCancer Radio | Leave a comment

Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World

June 28, 2010
evangelos terpos Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World

Evangelos Terpos, University of Athens

Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of therapy with the novel agents: thalidomide, lenalidomide and bortezomib in the “real world” setting. Professor Evangelos Terpos from the University of Athens discusses his groups findings on bone metabolism under novel agent therapy and assesses the impact of these drugs on survival among patients in Greece.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Posted in Oncology | Leave a comment